|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-6-30
|
|
pubmed:abstractText |
Emerging evidence suggests that epoetin alfa can be administered at extended intervals of up to 4 wk. This open-label, randomized study was performed to characterize the pharmacokinetic and pharmacodynamic profiles of four dosing regimens of epoetin alfa administered subcutaneously in anemic patients who had chronic kidney disease and were not on dialysis.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-12076240,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-12455725,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-1493082,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-15224803,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-15985516,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-16114787,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-17253886,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-17699416,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-18400964,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-18579671,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-2516609,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-2596476,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-7729331,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18417741-9797798
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1555-905X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1006-14
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18417741-Aged,
pubmed-meshheading:18417741-Aged, 80 and over,
pubmed-meshheading:18417741-Anemia,
pubmed-meshheading:18417741-Chronic Disease,
pubmed-meshheading:18417741-Dialysis,
pubmed-meshheading:18417741-Drug Administration Schedule,
pubmed-meshheading:18417741-Erythrocyte Count,
pubmed-meshheading:18417741-Erythropoietin,
pubmed-meshheading:18417741-Female,
pubmed-meshheading:18417741-Hematinics,
pubmed-meshheading:18417741-Hemoglobins,
pubmed-meshheading:18417741-Humans,
pubmed-meshheading:18417741-Injections, Subcutaneous,
pubmed-meshheading:18417741-Kidney Diseases,
pubmed-meshheading:18417741-Male,
pubmed-meshheading:18417741-Middle Aged,
pubmed-meshheading:18417741-Prospective Studies,
pubmed-meshheading:18417741-Recombinant Proteins,
pubmed-meshheading:18417741-Reticulocyte Count,
pubmed-meshheading:18417741-Treatment Outcome,
pubmed-meshheading:18417741-United States
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.
|
|
pubmed:affiliation |
Ortho Biotech Clinical Affairs, LLC, 430 Route 22 East, Bridgewater, NJ 08807, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
